Trinity Biotech plc acquires, develops, manufactures, and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market in the Americas, Africa, Asia, and Europe. The company offers clinical laboratory products, including diagnostic tests and instrumentation, which detect infectious diseases, such as lyme disease; sexually transmitted diseases consisting syphilis and herpes; SARS-CoV-2; and epstein barr, measles, mumps, toxoplasmosis, cytomegalovirus, rubella, varicella and other viral pathogens, as well as products for the in-vitro diagnostic testing for haemoglobin A1c used in the monitoring and diagnosis of diabetes, and identifying those who are at a risk of developing diabetes. It also develops, manufactures, and sells products in the immunofluorescence assay, enzyme-linked immunosorbent, western blot, and line immunoassay formats; and provides reagent products, such as ACE, bile acids, lactate, oxalate, and glucose-6-phosphate dehydrogenase for diagnosis of liver and kidney diseases, as well as haemolytic anaemia. In addition, the company sells raw materials to the life sciences industry and research institutes. It serves public health authorities, non-governmental organisations, and clinical and reference laboratories through its direct sales force, as well as through a network of independent distributors and strategic partners. Trinity Biotech plc was incorporated in 1992 and is headquartered in Bray, Ireland.

Trinity Biotech plc

Trinity Biotech plc is a public company, specializing in the development, manufacture and marketing of clinical diagnostic products.

msh id	COM:TRINITYBIOTECH
symbol	TRIB
name	Trinity Biotech plc
homepage url	https://www.trinitybiotech.com
country	IE
sector	Healthcare
industry	Medical - Diagnostics & Research
market	STOCKS
employee count	380
crunchbase url	-
linkedin url	-
founders	-

market cap	18.83M
enterprise value	-
stage	-
raised capital	-
valuation	-

monthly webtraffic	-
monthly webtraffic growth	-
growth score 14	-
growth score 28	-
growth score 90	-
growth score 365	-

revenue ltm	-
gross profit ltm	-
ebitda ltm	-
net income ltm	-
revenue ntm	-
gross profit ntm	-
ebitda ntm	-
net income ntm	-

growth cost and expenses	-0.15
growth cost of revenue	-0.27
growth depreciation and amortization	-0.33
growth ebitda	-0.73
growth ebitda ratio	-1.27
growth eps	-
growth eps diluted	-
growth general and administrative expenses	-
growth gross profit	-0.16
growth gross profit ratio	0.1

COM:TRINITYBIOTECH

Trinity Biotech plc

Last Close

1.30

21/11 21:00

Market Cap

18.83M

Beta: -

Volume Today

21.36K

Avg: -

Company Information

Market Metrics

Web & Growth Metrics

LTM & NTM Metrics

Growth & Performance Metrics

Operating Metrics

Balance Sheet Metrics

Financial Metrics (2022-2026)

cost and expenses	72.91M
cost of revenue	72.91M
depreciation and amortization	1.78M
ebitda	-14.3M
ebitda ratio	-0.25
eps	-15.69
eps diluted	-15.69
operating expenses	34.59M
operating income	-16.08M
operating income ratio	-0.28

accounts receivables	-
capital expenditure	-2.7M
cash at beginning of period	6.58M
cash at end of period	3.69M
inventory	19.93M
working capital ttm	38.16M

	2022	2023	2024	2025	2026
Revenue Metrics
Revenue	-	-	-	-	-
Revenue Growth	-	-	-	-	-
Revenue Multiple	-	-	-	-	-
Profit Metrics
Gross Profit	-	-	-	-	-
Gross Profit Growth	-	-	-	-	-
Gross Profit Multiple	-	-	-	-	-
EBITDA Metrics
EBITDA	-	-	-	-	-
EBITDA Growth	-	-	-	-	-
EBITDA Multiple	-	-	-	-	-
Net Income Metrics
Net Income	-	-	-	-	-
Net Income Growth	-	-	-	-	-
Net Income Multiple	-	-	-	-	-